SEC Form 4 · accession 0001395064-26-000335
TAKEDA PHARMACEUTICAL CO LTD · TAK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew Stewart Plump
Officer — President, R&D · Director
Period of report
Sep 2, 2026
Accepted (ET)
Sep 3, 2026 · 9:49 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001395064
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| American Depositary Shares | Sep 2, 2026 | S | 116,191 | $18.49 | D | 145,465 | I | By Trust |
| American Depositary Shares | holding | — | — | — | 766,569 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported herein were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 15, 2026.